Background-Interleukin-1 increases nitrooxidative stress. We investigated the effects of a human recombinant interleukin-1a receptor antagonist (anakinra) on nitrooxidative stress and vascular and left ventricular function. Methods and Results-In an acute, double-blind trial, 23 patients with rheumatoid arthritis were randomized to receive a single injection of anakinra (150 mg SC) or placebo and, after 48 hours, the alternative treatment. At baseline and 3 hours after the injection, we assessed (1) coronary flow reserve, aortic distensibility, systolic and diastolic (Em) velocity of the mitral annulus, and E to Em ratio (E/Em) using echocardiography;
patients. We also measured malondialdehyde and nitrotyrosine as markers of nitrooxidative stress, ET-1 as a protein that affects vascular reactivity, and IL-6 and CRP as inflammatory markers.
Methods

Study Cohort
Acute Study
We examined 23 patients (mean age 57Ϯ17 years, 17 females) with RA (American Rheumatism Association criteria 31 ) who had an inadequate response to disease-modifying antirheumatic drugs and corticosteroids and who were eligible to receive anakinra (Table 1) . This group of patients participated in an acute, randomized, crossover, and placebo-controlled trial with anakinra.
We used the following equation to calculate the composite disease activity score (DAS), which utilizes CRP, the visual analogue score (VAS) of well-being, and the number of tender and swollen joints (from a total of 28 joints assessed): DASϭ ͌0.56ϫnumber of tender jointsϩ͌0.28ϫnumber of swollen jointsϩ[0.70ϫln(CRP)]ϩ(0.014ϫVAS). 30 Changes in DAS are associated with improvement in physical activity. 32 
Chronic Study
After completion of the acute study, the 23 patients with RA participated in a chronic, nonrandomized study with anakinra treatment (150 mg SC once daily) for 30 days. This group was compared with a group of 19 RA patients of similar age, sex, and DAS (Table  1) who also had an inadequate response to treatment with diseasemodifying antirheumatic drugs and prednisolone and who were treated with an increase of their initial dose of prednisolone by 5 mg for 30 days.
None of the patients had cardiovascular or renal disease or ischemia during thallium scintigraphy or dobutamine stress. Patients with known or suspected coronary artery disease were excluded to ensure that measurement of CFR would reflect the status of coronary microcirculation and not the effects of epicardial coronary artery stenosis.
Twenty-three asymptomatic subjects of similar age and sex as the RA patients and with a normal ECG, echocardiogram, and treadmill test were selected as healthy control subjects among subjects attending the cardiology outpatient clinic. The study was approved by the hospital's research committee, and all patients provided written informed consent.
Ultrasonography
All ultrasonography studies were performed with a Vivid 7 (GE Medical Systems, Horten, Norway) machine; they were digitally stored and analyzed by 2 observers (I.I. and I.P.) blinded to clinical and laboratory data and using a computerized station (Echopac GE, Horten, Norway). All patients and control subjects had adequate images for analysis.
Echocardiography
Aortic systolic (AoS) and diastolic (AoD) diameter were measured by 2D-guided M-mode echocardiography. Pulse pressure (PP) was simultaneously obtained by cuff sphygmomanometry. We calculated aortic strain as ASϭ100ϫ(AoSϪAoD)/AoD and aortic distensibility as ADϭ2ϫ(AoSϪAoD)/(AoDϫPP)(cm 2 ϫdyn (Ϫ1) ϫ10 (Ϫ6) ), as previously published. 29 Coronary flow velocities in the left anterior descending coronary artery were obtained with color-guided pulse-wave Doppler from long-axis apical projections with a 7-MHz transducer. 27 The maximal velocity (CF-Vmax) and velocity time integral (VTI) of the overall coronary flow wave (CF-VTI) and its diastolic component (CF-VTId) were measured at baseline and after adenosine infusion (140 g · kg Ϫ1 · min Ϫ1 ) for 3 minutes. 27 CFR was calculated as the ratio of hyperemic to resting CF-VTId. 27 Measurements from 3 cardiac cycles were averaged. Interobserver and intraobserver variabilities were calculated as the SD of the differences between the first and second measurements and expressed as a percentage of the average value. Interobserver and intraobserver variabilities of these measurements were 5% and 2%, respectively, as reported in previous studies. 21, 27 Myocardial velocities were recorded with tissue Doppler imaging. The sample volume was placed in the septal, lateral, inferior, and anterior corners of the mitral annulus in the apical 4-and 2-chamber Values for disease duration are median and interquartile range. ACE indicates angiotensin-converting enzyme.
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views to record the systolic velocity (Sm), early diastolic velocity (Em), and late diastolic velocity (Am). 28 The mean value of the velocities at the 4 annular sites was used. The ratio of the mitral E wave measured by pulsed-wave Doppler to the Em was calculated as an index of LV diastolic filling pressures. 28 Interobserver and intraobserver variability of these measurements were 3% and 1.7%, respectively.
Endothelial Function
FMD and nitrate-induced vasodilation of the brachial artery were determined according to a previously published methodology. 26 Before the study, all subjects abstained from alcohol, caffeine, and food for 8 hours and ceased taking any vasoactive medications for 24 hours. Interobserver and intraobserver variabilities of the brachial artery diameter were 0.08Ϯ0.19 and 0.1Ϯ0.12 mm, and the day-to day variability of FMD was 1.1Ϯ1%. 26
Pulse-Wave Velocity
PWV was measured with the Complior apparatus (Artech Medical, Pantin, France). 30 Waveforms were obtained over the right common carotid and the femoral artery.
Laboratory Assays
CRP was measured by high-sensitivity, particle-enhanced immunonephelometry (Dade Behring, Marburg, Germany; measurement range 0.175 to 1100 mg/L 
Study Protocols
Acute Study
In 23 patients with RA, we used a double-blind, crossover, placebocontrolled protocol to study the effects of anakinra on biochemical, vascular, and LV function markers. All patients had baseline measurements of the examined markers. Measurement of PWV and echocardiography preceded the FMD study. Patients were randomized to receive 1 subcutaneous injection of 150 mg of anakinra (nϭ12) or placebo (nϭ11). Assessment of the examined markers was repeated 3 hours after the injection, in accordance with the half-life of anakinra. Forty-eight hours after the first examination, patients were crossed over to the alternate treatment (placebo or anakinra), and measurement of the examined markers was repeated. The 48-hour interval between the 2 consecutive studies was chosen to ensure a sufficient washout period for anakinra in accordance with its half-life. 20
Chronic Study
During a chronic, nonrandomized study, 23 patients with RA who received anakinra (150 mg SC once daily) for 30 days were compared with 19 RA patients who received an increased dose of prednisolone for 30 days. Both groups had measurements of biochemical, vascular, and LV function markers at baseline and after 30 days of treatment. The healthy control subjects had a single baseline measurement of the examined markers.
Statistical Analysis
On the basis of 1Ϯ1% (meanϮSD) 26 and 5% variability 21 for the measurement FMD and coronary flow velocities respectively, we assumed that a 25% change in vascular markers was clinically significant. In a previous study, 21 the mean absolute change in CFR after intervention was Ϫ0.86 (range Ϫ1.36 to Ϫ0.37; 23% change). Thus, with a mean difference of 0.86, a variability of the difference of 1.36, an ␣ϭ0.05 (2-sided), and a power of 80%, the sample size needed was calculated to be 23 patients for within-patient comparisons. In our previous studies, 26 the mean absolute change in FMD after intervention was 2.5%, and the variability of this change was 3%; thus, with an ␣ϭ0.05 (2-sided) and a power of 80%, the required sample size was calculated to be 13 patients.
Categorical data were compared among patients treated with anakinra or prednisolone and healthy control subjects by contingency tables (P value in Table 1 ) and between each treatment group and healthy control subjects by the 2 test or Fisher exact test when 5 or fewer patients were included in each cell (Table 1 ). Continuous variables were tested for normality with the Kolmogorov-Smirnov test. Normally distributed variables are given as meanϮSD. Spearman correlation analysis was used to determine bivariate correlations. Because biomarkers had a nonnormal distribution, data are expressed as median (interquartile range) and were analyzed after transformation into ranks. 17 ANOVA (general linear model, SPSS 13, SPSS Inc, Chicago, Ill) for repeated measurements was applied for the following comparisons: (1) in the acute study, for measurements of the examined markers at baseline, 3 hours after placebo, and 3 hours after anakinra; and (2) in the chronic study, for the effects of anakinra versus prednisolone, with measurements at baseline and 30 days after treatment used as a within-subject factor and type of treatment used as a between-subject factor. The F and P values of the interaction between time of measurement of the examined markers and type of treatment were calculated. The Greenhouse-Geisser correction was used when the sphericity assumption, as assessed by Mauchly's test, was not met. Post hoc comparisons were performed with Bonferroni correction.
The percent changes of the examined indices between baseline and after anakinra or between baseline and after placebo were compared with the Wilcoxon signed rank test (biomarkers) or paired t test (vascular and LV function markers). The percent changes of the examined indices between baseline and 30 days in the anakinra group versus changes in the prednisolone group were compared with the Mann-Whitney test (biomarkers) or unpaired t test (vascular and LV function markers). Comparisons between healthy control subjects and each treatment group at baseline or at 30 days were performed with unpaired t test (vascular and LV function indices) and Mann-Whitney test (biomarkers). Statistical significance was considered at PϽ0.05.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Patient characteristic are shown in Table 1 . Twenty patients complained of mild erythema at the injection site. None were withdrawn from the study because of adverse effects or inadequate response to treatment.
Acute Study
Biochemical Markers
Compared with baseline, the percent reduction in IL-6, malondialdehyde, nitrotyrosine, and ET-1 levels was greater after anakinra than after placebo (IL-6 Ϫ29Ϯ3% versus 0.9Ϯ1%, Pϭ0.003; malondialdehyde Ϫ25Ϯ5% versus 9Ϯ3%, Pϭ0.03; nitrotyrosine Ϫ38Ϯ5% versus Ϫ11Ϯ3%, Pϭ0.001; and ET-1 Ϫ36Ϯ7% versus Ϫ11%Ϯ3%, PϽ0.001; Table 2 ). No changes were observed in CRP or lipid levels after treatment.
Vascular Function
Compared with baseline, FMD increased by 45Ϯ5% after anakinra versus a decrease of 9Ϯ3% after placebo (PϽ0.001; Table 3 ). Nitrate-induced vasodilation remained unchanged (Pϭ0.2). The percent increase in resting and hyperemic CF-Vmax, CF-VTI, and CF-VTId was greater after anakinra than after placebo (rest: 12Ϯ2% versus Ϫ3.8Ϯ3%, 13Ϯ3% versus 3.8Ϯ3%, and 11%Ϯ2 versus Ϫ8Ϯ6%, respectively; hyperemia: 27Ϯ2% versus 1.5Ϯ2%, 31Ϯ3% versus 2Ϯ2%, and 35Ϯ3% versus Ϫ0.4%Ϯ1, respectively; PϽ0.001 for all comparisons). CFR was increased by 29Ϯ2% after anakinra versus 4Ϯ2% after placebo (PϽ0.001).
The percent increase in aortic distensibility and strain was greater after anakinra than after placebo (45Ϯ7% versus 2Ϯ2% and 54Ϯ9% versus Ϫ4Ϯ3%, respectively; PϽ0.001 for all comparisons). Heart rate, systolic and diastolic blood pressure, pulse pressure, and PWV remained unchanged (Pϭ0.1, Pϭ0.41, Pϭ0.44, Pϭ0.9, and Pϭ0.7, respectively).
LV Function
Compared with baseline, the Sm increased by 13Ϯ1% after anakinra versus a 1Ϯ0.9% decrease after placebo (Pϭ0.001). E/Em was reduced by 15Ϯ1% after anakinra versus 7Ϯ1% after placebo (Pϭ0.005; Table 3 ).
Chronic Treatment
The DAS was reduced from 5.1Ϯ0.9 to 3.4Ϯ0.9 after anakinra and from 5.3Ϯ1.1 to 4.1Ϯ0.9 after prednisolone (F for interactionϭ6.1, Pϭ0.018; 34% versus 22% change, Pϭ0.019).
Biochemical Markers
Compared with baseline, the percent reduction in IL-6, malondialdehyde, nitrotyrosine, CRP, and ET-1 was greater after anakinra than after prednisolone (IL-6 Ϫ61Ϯ8% versus Ϫ41Ϯ9%, Pϭ0.02 malondialdehyde Ϫ33Ϯ2% versus 3Ϯ2%, Pϭ0.006; nitrotyrosine Ϫ50Ϯ8% versus 0.5Ϯ1%, Pϭ0.006; CRP Ϫ80Ϯ9% versus Ϫ58Ϯ6%, Pϭ0.004; and ET-1 Ϫ40Ϯ7% versus Ϫ22Ϯ4%, Pϭ0.04). There were no significant changes in lipid levels after treatment. Patients taking anakinra had higher baseline levels of biomarkers than healthy control subjects (malondialdehyde 2. P value refers to post hoc analysis (Bonferroni correction) by ANOVA for repeated measurements between baseline and those taken 3 hours after placebo or 3 hours after anakinra. P value refers to post hoc analysis (Bonferroni correction) by ANOVA for repeated measurements between baseline and measurements taken 3 hours after placebo or 3 hours after anakinra.
2.0] pg/mL; and CRP 11.6 [6.5 to 35] versus 1.4 [0.01 to 2.0] mg/L, PϽ0.05). Malondialdehyde, ET-1, and CRP levels became similar between patients and control subjects after treatment with anakinra. Conversely, patients treated with prednisolone had higher baseline and posttreatment levels of biomarkers than healthy control subjects (Table 4 ; PϽ0.05).
Vascular Function
Compared with baseline, the percent increase in FMD and CFR was greater after anakinra than after prednisolone (47Ϯ5% versus Ϫ14Ϯ6% and 35Ϯ5% versus Ϫ4Ϯ2%, respectively; PϽ0.001 for all comparisons; Table 5 ). The percent increase in all coronary flow indices was higher after anakinra than after prednisolone (PϽ0.05). Nitrate-induced vasodilation was similar between the 2 treatment groups (F for interactionϭ0.1, Pϭ0.7). Aortic distensibility and strain showed a 3-fold increase after anakinra compared with a 7Ϯ3% and 11Ϯ3% increase after prednisolone (PϽ0.001 for all comparisons). The anakinra group had lower baseline FMD, CFR, aortic distensibility, and aortic strain than healthy control subjects (FMD 5.3Ϯ3.0% versus 8.1Ϯ2.3%, Pϭ0.004; CFR 2.39Ϯ0.6 versus 3.10Ϯ0.9, PϽ0.001; aortic distensibility 1.56Ϯ1.1 versus 3.71Ϯ1.1 cm 2 · dyne Ϫ1 · 10 Ϫ6 , PϽ0.001; aortic strain 3.35Ϯ1.7% versus 8.12Ϯ2.3%, PϽ0.001). These indices became similar between patients and control subjects after treatment. Hyperemic CF-VTI and CF-VTId were lower in patients than in control subjects before anakinra treatment (29.1Ϯ8 versus 33.2Ϯ4 cm, Pϭ0.04 and 22.7Ϯ7.0 versus 26.1Ϯ3.2 cm, Pϭ0.02, respectively) and became higher in patients than in control subjects after treatment (43.1Ϯ10.1 cm, Pϭ0.01 and 32.7Ϯ9.1 cm, Pϭ0.004, respectively). Conversely, patients treated with prednisolone had lower FMD, CFR, aortic distensibility, and aortic strain than control subjects both before and after treatment (PϽ0.05). Hyperemic coronary flow markers were lower in patients than in control subjects before prednisolone treatment (PϽ0.05) and became similar between patients and control subjects after treatment. Abbreviations as in Table 3 . P value refers to comparisons between baseline and measurements taken after 1 month. *PϭNS for comparisons between patients taking anakinra and patients taking prednisolone at baseline for all variables.
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LV Function
Compared with baseline, the percent improvement in Sm, Em/Am, and E/Em was greater after anakinra than after prednisolone (20Ϯ2% versus 1.1Ϯ1%, Pϭ0.001; 19Ϯ2% versus 5Ϯ1%, Pϭ0.04; and Ϫ21Ϯ2% versus 4.4Ϯ2%, Pϭ0.005, respectively). Both treatment groups had lower baseline Sm than control subjects (anakinra 8.4Ϯ2.1 cm/s and prednisolone 8.5Ϯ1.6 cm/s versus control subjects 9.3Ϯ1.6 cm/s, Pϭ0.028 and Pϭ0.03, respectively). After treatment, the anakinra group had similar Sm as control subjects (Pϭ0.9), whereas the prednisolone group had lower Sm than control subjects (Pϭ0.03). Em/Am and E/Em remained higher in patients (Table 5 ) than in control subjects (Em/Am 1.6Ϯ0.6 and E/Em 6Ϯ1.1) throughout the study (PϽ0.05).
Interrelation of Changes After Treatment
The percent increase in CFR was related to the reduction in nitrotyrosine and malondialdehyde 3 hours (r s ϭ0.50, Pϭ0.01 and r s ϭ0.49, Pϭ0.02, respectively) and 30 days (r s ϭ0.53, Pϭ0.005 and r s ϭ0.50, Pϭ0.01, respectively) after anakinra. Modest correlations were observed between the changes in CFR, IL-6, and ET-1 after anakinra (PϽ0.05). The percent increase in FMD was equally related to the reduction of malondialdehyde, nitrotyrosine, and ET-1 at 3 hours and 30 days after anakinra (PϽ0.05). The percent increase in aortic distensibility 3 hours and 30 days after anakinra was related to the reduction in malondialdehyde (r s ϭ0.63, Pϭ0.001 and r s ϭ0.55, Pϭ0.004), nitrotyrosine (r s ϭ0.52, Pϭ0.009 and r s ϭ0.50, Pϭ0.01,) IL-6 (r s ϭ0.62, Pϭ0.002 and r s ϭ0.60, Pϭ0.004), and ET-1 (r s ϭ0.50, Pϭ0.01 and r s ϭ0.49, Pϭ0.02). Similar associations were observed for aortic strain (PϽ0.05). Both the percent increase in Sm and the reduction in E/Em were related to the reduction in IL-6 and nitrotyrosine at 3 hours (PϽ0.001) and 30 days (PϽ0.001) after anakinra. The percent increase in FMD was related to the increase in resting and hyperemic CF-VTId, CFR (PϽ0.05), aortic strain, and aortic distensibility (PϽ0.05) after anakinra.
Discussion
In an acute, double-blind, crossover, placebo-controlled trial of patients with RA, we have shown that administration of IL-1ra (anakinra) caused a greater reduction of nitrooxidative stress, IL-6, and ET-1 than placebo. After acute anakinra administration, changes in biomarkers were associated with a parallel improvement in vascular and LV function. After 30 days of treatment, the improvement in biomarkers and vascular and LV function was greater in patients treated with anakinra than in patients treated with prednisolone.
Acute Study
Effects of IL-1 Inhibition on Vascular Function
Adenosine-induced CFR is thought to be endothelium dependent. [21] [22] [23] IL-1 may cause endothelial dysfunction and, consequently, an impaired CFR through increased nitrooxidative stress 9,10 and release of ET-1. 8, 14 Reduction of nitrooxidative stress rapidly restores endothelium-dependent relaxation of rat aorta 12 and coronary vasomotor function. 33 In an acute, double-blind trial, we have shown that an IL-1ra reduced ET-1, IL-6, malondialdehyde, and nitrotyrosine after 3 hours of treatment compared with placebo. Furthermore, we demonstrated a parallel improvement in FMD, resting and hyperemic coronary flow, CFR, aortic distensibility, and aortic strain after anakinra treatment. Of all biomarkers, the reduction in nitrotyrosine and malondialdehyde demonstrated the highest correlation with improvement of endothelial, coronary, and aortic function.
Experimental studies have shown that IL1ra (1) reduced oxidative burst as assessed by peroxynitrite by 2 hours 34 ; (2) completely abolished inflammation, oxidative stress, and the resultant tissue damage 18 when given 30 minutes before and 3 hours after the induction of oxidative lung injury; and (3) diminished the effects of IL-1-induced free radical production on fibrinolysis within 1 hour and thus improved endothelial function in microvessels. 35 Therefore, studies suggest a rapid effect of IL-1ra on oxidative stress that leads to an early improvement in microcirculation and vascular function. 35 Antioxidant treatment has been shown to improve FMD and CFR within 3 hours 22, 23, 25 in humans. Therefore, in the present study, the acute beneficial effects of IL-1 inhibition on vascular function may be related to the concomitant reduction in nitrooxidative stress.
In the present study, the reduction in circulating ET-1 after anakinra was also related to the improvement in FMD and CFR. Thus, the acute reduction of ET-1 by anakinra may also have contributed to the rapid improvement in vascular function.
IL1-ra reversed the effects of IL-1 on aortic function in rats within 5 hours 36 through inhibition of nuclear factor-B and subsequent reduction of inducible nitric oxide synthase production, blocked IL-1-mediated activation of the nuclear factor-B within 5 minutes, 37 and reduced IL-1-induced IL-6 production within 2 hours after stimulation 37 through inhibition of nuclear factor-B. Thus, a rapid inhibition of nuclear factor-B by anakinra may explain the association between the improved aortic function and reduction in IL-6 in the acute phase of the present study.
Increased nitrooxidative stress mediates a depressed endothelium-dependent relaxation of aorta in experimental models of RA. 12 Nitric oxide and/or endothelin regulates local arterial distensibility in vivo. 7, 24 In the present study, the acute reduction in malondialdehyde, nitrotyrosine, and ET-1 by anakinra, was related to improved aortic function. This finding suggests that the combined reduction in nitrooxidative stress and endothelin after IL-1 inhibition may have caused the early improvement in aortic function. The lack of a significant effect of anakinra treatment on PWV suggests either that a single dose of anakinra was not sufficient to restore function along the entire length of the thoracicabdominal aorta or that the present study did not have sufficient power to detect subtle changes in PWV. The ascending aorta is a more elastic vessel than the abdominal aorta and its branches. Thus, the aortic root may respond more rapidly than the more rigid abdominal aorta to changes in oxidative stress, nitric oxide, and endothelin levels that lead to concomitant changes of its distensibility. 38 A large study of patients with RA and comorbidities including coronary artery disease 19 has shown that there were no differences in cardiovascular events or serious infections after anakinra compared with placebo. Thus, anakinra has a more favorable safety profile than other humoral regimens that improve endothelial function. 39
Effects of IL-1 Inhibition on LV Function
IL-1 activity may cause reversible myocardial dysfunction through production of peroxynitrate and IL-6. 11, [15] [16] [17] In the present study, the reduction in IL-6 and nitrotyrosine was related to an acute improvement in LV function after anakinra. This association is in line with studies demonstrating that IL-1ra rapidly inhibits IL-6 production and reduces peroxynitrate 18,34 -37 and that the IL-6 -mediated negative inotropic effect is completely reversed by 40 minutes after removal of this cytokine in vitro. 16, 17 Additionally, the significant improvement in CFR and aortic function may have contributed to the improvement in LV performance after anakinra.
Chronic Study
In the present study, the improvement in biomarkers and vascular and LV function was greater in the anakinra group than in the prednisolone group after 30 days of treatment. The acute beneficial effects of anakinra on nitrooxidative stress and vascular and LV function were maintained after chronic treatment compared with the conventional antiinflammatory regimens. Compared with healthy control subjects, both treatment groups had abnormal baseline biomarkers and vascular and LV function; however, malondialdehyde, ET-1, CRP, CFR, FMD, aortic function, and Sm became similar between patients and healthy control subjects after anakinra but not after prednisolone treatment. This finding suggests that the effects of IL-1 inhibition on oxidative stress and inflammation may lead to normalization of vascular function.
Study Limitations
The study design does not enable exploration of causality for the changes in vascular and LV function after anakinra treatment. Although the acute study timings were based on the pharmacokinetics of anakinra, 20 there may have been a carryover effect in the crossover phase. However, the persistent effects of anakinra compared with prednisolone in the chronic study, in which no carryover effects occur, support the significant effects of anakinra on vascular and LV function. Because RA patients with coronary artery disease were excluded, the effects of anakinra in the presence of coronary artery disease were not explored in the present study. The large number of comparisons in the present study may have caused a type I error. Improved physical activity after anakinra as reflected by the reduced DAS 32 may have contributed to the improvement in biochemical, vascular, and LV parameters. The noninvasive assessment of vascular and LV function should also be acknowledged as a limitation. 26 -30 
Conclusions
In the present study, we have shown that administration of a commercially available IL-1ra improves vascular and LV function and is related to a concomitant reduction in nitrooxidative stress and ET-1 levels in patients with RA.
Disclosures
None.
